Europe veterinary healthcare is primarily driven by increasing initiatives by various governments, improved animal healthcare, and rising animal adoption in European countries. According to the People’s Dispensary for Sick Animals, in 2018, 49% of the adults in the United Kingdom owned a pet. Among them, 25% of the adults owned a pet cat (with an estimated population of 11.1 million pet cats) and 24% of the adults owned a pet dog (with an estimated population of 8.9 million pet dogs).

Furthermore, advancements in animal diagnostic technologies for accurate diagnostics and the presence of some of the key market players in the region expected to propel the market growth. For instance, in April 2019, Vita Animal Health has launched a range of veterinary specific animal health supplements in the United Kingdom. The range is already established in several European countries and includes products to support cardiovascular, joint and skin health in cats, dogs, rabbits and horses.

However, the increasing costs of animal testing and veterinary services, shortage of farmworkers and veterinarians, and the use of counterfeit medicines are restraining the growth of the European veterinary healthcare market.

Key Market Trends

Anti-infectives are Expected to Have Significant Share

  • Anti-infectives are used for the prevention and treatment of infections in animals. There is a wide range of anti-infectives developed and manufactured by different animal healthcare companies.
  • Bacterial infection (pyoderma) in companion animals is mainly caused by two organisms - Staphylococcus pseudintermedius and Staphylococcus schleiferi. Some of the top companies of veterinary anti-infectives in Europe are Zoetis, Ceva Animal Healthcare, and Boehringer Ingelheim, among others. The Responsible Use of Medicines in Agriculture (RUMA), in Europe, provides guidelines for the responsible use of antimicrobials on cattle, sheep, and pigs, ensuring that the dairy farmers meet the antibiotic residue standard.
  • However, antimicrobial resistance is a major concern that is threatening the effective prevention and treatment of infections caused by bacteria, parasites, viruses, and fungi. The initiatives by the British government, such as the five-year anti-microbial resistance strategy 2013-2018, which promotes the implementation of animal health laws and the development of anti-microbial agents, are expected to aid the growth of the market.



Competitive Landscape

The major players in the European veterinary healthcare market are engaging in various growth strategies, such as collaborations, partnerships, agreements, mergers, and acquisitions, in order to enhance their market presence.
In June 2018, Regeneron entered into a collaboration agreement with Zoetis, to research antibody therapies to be used in animal health. In 2018, Boehringer Ingelheim announced its plans to invest EUR 65 million in France, for the production of avian vaccines, as its demand increased due to an increase in poultry consumption.

The key market players operating in European veterinary healthcare market include Zoetis Animal Healthcare, Boehringer Ingelheim, Ceva , Elanco and Vetoquinol among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support